Location: New York,NY, USA
Actinium Pharmaceuticals, Inc. develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for patients with relapsed or refractory cancer who have failed existing therapies. We are deploying our technology platform, which we believe to be industry-leading, and intellectual property with over 230 issued and pending patents worldwide, to develop ARCs and next-generation radiotherapies against validated cancer targets. Our strategy is to build an integrated, specialty radiotherapeutics company using the power of our platform technologies to deliver new treatment options for patient populations living with high unmet medical needs in hematology and oncology.
Radiotherapeutics leverage the cell-killing power of linear energy transfer, which we believe is unmatched by other technologies and we also believe that relapsed or refractory disease is an area where radiotherapeutics can succeed over other approaches. Our product candidates, Iomab-B and Actimab-A, have the potential to improve outcomes for patients with relapsed or refractory acute myeloid leukemia (r/r AML) and address the significant unmet need for better outcomes from treatment with therapeutics or from undergoing a bone marrow transplant. Iomab-ACT is our next-generation CD45 targeted conditioning agent being developed for cell and gene therapies for both malignant and non-malignant hematologic indications. We are developing Iomab-ACT with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-ACT is currently being studied in three clinical trials, including with a commercial CAR-T therapy, prior to allogeneic BMT for patients with sickle cell disease.
Our R&D capabilities have the potential to yield differentiated, high-value ARC programs that demonstrate our experience across multiple validated cancer targets and isotopes and cover broad areas of focus leveraging our clinical development experience across hematology, targeted conditioning, solid tumors, and next generation ARCs.
Actinium is seeking a highly motivated and skilled Senior Research Associate to actively support the Company's promising R&D strategy for the development of novel therapeutic agents and related technology. The qualified individual will have prior experience in an academic or industry lab setting and can independently perform high quality work. Experience in protein conjugation and its purification, and analytical techniques to characterized protein conjugates are required. Experience with handling radioactivity or radio-conjugates is preferred. This position will report to the Senior Director, R&D.
Duties and responsibilities
Design and independently perform bioconjugation and radiolabeling of biomolecules.
Work cross-functionally to deliver radiolabeled compounds for in vitro and in vivo evaluation.
Design, develop and execute experiments to further characterize conjugates and radiolabeled compounds
Prepare technical reports and presentations to communicate experimental outcomes to internal teams and management
Manage and maintain equipment, reagents, and the dedicated laboratory environment needed to carry out assignments.
Maintain highly organized records to enable optimization and assessment of reproducibility.
Track inventory of reagents critical to conjugation and radiolabeling development and make purchases to replenish when necessary.
Perform other duties as assigned.
Qualifications
Minimum qualifications required to successfully perform the job are: